BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 26077352)

  • 1. Update on Testosterone Replacement Therapy in Hypogonadal Men.
    Leung KM; Alrabeeah K; Carrier S
    Curr Urol Rep; 2015 Aug; 16(8):57. PubMed ID: 26077352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late-life onset hypogonadism: a review.
    Bassil N; Morley JE
    Clin Geriatr Med; 2010 May; 26(2):197-222. PubMed ID: 20497841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EMAS position statement: Testosterone replacement therapy in older men.
    Kanakis GA; Pofi R; Goulis DG; Isidori AM; Armeni E; Erel CT; Fistonić I; Hillard T; Hirschberg AL; Meczekalski B; Mendoza N; Mueck AO; Simoncini T; Stute P; van Dijken D; Rees M; Lambrinoudaki I
    Maturitas; 2023 Dec; 178():107854. PubMed ID: 37845136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
    Rosen RC; Wu F; Behre HM; Porst H; Meuleman EJH; Maggi M; Romero-Otero J; Martinez-Salamanca JI; Jones TH; Debruyne FMJ; Kurth KH; Hackett GI; Quinton R; Stroberg P; Reisman Y; Pescatori ES; Morales A; Bassas L; Cruz N; Cunningham GR; Wheaton OA;
    J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone Replacement Therapy in Hypogonadal Men Following Prostate Cancer Treatment: A Questionnaire-Based Retrospective Study among Urologists in Bavaria, Germany.
    Kühn CM; Strasser H; Romming A; Wullich B; Goebell PJ
    Urol Int; 2015; 95(2):153-9. PubMed ID: 25677365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
    Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
    Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
    Rhoden EL; Morgentaler A
    J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
    Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
    JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone and the prostate: implications for the treatment of hypogonadal men.
    Holyoak JD; Crawford ED; Meacham RB
    Curr Urol Rep; 2008 Nov; 9(6):500-5. PubMed ID: 18947516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular benefits and risks of testosterone replacement therapy in older men with low testosterone.
    Chrysant SG; Chrysant GS
    Hosp Pract (1995); 2018 Apr; 46(2):47-55. PubMed ID: 29478348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices.
    Miner M; Canty DJ; Shabsigh R
    Postgrad Med; 2008 Sep; 120(3):130-53. PubMed ID: 18824832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone Therapy: What We Have Learned From Trials.
    Corona G; Torres LO; Maggi M
    J Sex Med; 2020 Mar; 17(3):447-460. PubMed ID: 31928918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms.
    Leibowitz RL; Dorff TB; Tucker S; Symanowski J; Vogelzang NJ
    BJU Int; 2010 May; 105(10):1397-401. PubMed ID: 19912179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men With Late-Onset Hypogonadism.
    Santella C; Renoux C; Yin H; Yu OHY; Azoulay L
    Am J Epidemiol; 2019 Sep; 188(9):1666-1673. PubMed ID: 31145457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypogonadism and Testosterone Therapy: Associations With Cardiovascular Risk.
    Maganty A; Osterberg EC; Ramasamy R
    Am J Mens Health; 2015 Jul; 9(4):340-4. PubMed ID: 24972716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone Replacement Therapy and Mortality in Older Men.
    Hackett GI
    Drug Saf; 2016 Feb; 39(2):117-30. PubMed ID: 26482385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of testosterone replacement therapy on sexual function and glycemic control among hypogonadal men with type 2 diabetes mellitus.
    Shigehara K; Konaka H; Kato Y; Iijima M; Nakashima K; Kawaguchi S; Nohara T; Izumi K; Namiki M; Mizokami A
    Int J Impot Res; 2019 Jan; 31(1):25-30. PubMed ID: 30135606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.